H C MAGUIRE Jr
Overview
Explore the profile of H C MAGUIRE Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berd D, Sato T, Cohn H, MAGUIRE Jr H, Mastrangelo M
Int J Cancer
. 2001 Dec;
94(4):531-9.
PMID: 11745440
A human cancer vaccine composed of autologous tumor cells modified with the hapten dinitrofluorobenzene (DNP) induces cell-mediated immunity to the tumor cells and the development of inflammatory responses within metastatic...
2.
MAGUIRE Jr H, Berd D, Lattime E, McCue P, Kim S, Chapman P, et al.
Cancer Biother Radiopharm
. 2000 Jun;
13(1):13-23.
PMID: 10850338
R24 is a mouse IgG3 monoclonal antibody with specificity for the disialoganglioside GD3. Most human melanomas have substantial surface GD3; in addition, a significant proportion of T lymphocytes display surface...
3.
Mastrangelo M, MAGUIRE Jr H, Eisenlohr L, Laughlin C, Monken C, McCue P, et al.
Cancer Gene Ther
. 1999 Oct;
6(5):409-22.
PMID: 10505851
Seven immunocompetent, revaccinated patients with surgically incurable cutaneous melanoma underwent treatment of dermal and/or subcutaneous metastases with twice-weekly intratumoral injections of escalating doses (10(4)-2 x 10(7) plaque-forming units (PFU)/lesion; 10(4)-8...
4.
Halak B, MAGUIRE Jr H, Lattime E
Cancer Res
. 1999 Feb;
59(4):911-7.
PMID: 10029084
Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of...
5.
Berd D, Kairys J, Dunton C, Mastrangelo M, Sato T, MAGUIRE Jr H
Semin Oncol
. 1998 Dec;
25(6):646-53.
PMID: 9865679
We have devised a novel approach to active immunotherapy based on modification of autologous cancer cells with the hapten, dinitrophenyl (DNP). The treatment program consists of multiple intradermal injections of...
6.
Kim J, MAGUIRE Jr H, Nottingham L, MORRISON L, Tsai A, Sin J, et al.
J Interferon Cytokine Res
. 1998 Aug;
18(7):537-47.
PMID: 9712370
Cytokines are important regulators of the immune response. They influence immune expression, the development of immunologic memory, and regulation of antigen-specific and nonspecific immune activation as well as allergic responses....
7.
Mastrangelo M, Sato T, Lattime E, MAGUIRE Jr H, Berd D
Cancer Treat Res
. 1998 May;
94:35-50.
PMID: 9587681
No abstract available.
8.
MAGUIRE Jr H, Ketcha K, Lattime E
J Interferon Cytokine Res
. 1998 Feb;
17(12):763-8.
PMID: 9452364
Various cytokines have been shown to modulate the acquisition and expression of delayed-type hypersensitivity. In a mouse model, we tested the notion that neutralization of interleukin-10 (IL-10), a cytokine that...
9.
Berd D, MAGUIRE Jr H, Schuchter L, Hamilton R, Hauck W, Sato T, et al.
J Clin Oncol
. 1997 Jun;
15(6):2359-70.
PMID: 9196151
Purpose: To determine whether treatment with an autologous whole-cell vaccine modified with the hapten dinitrophenyl (DNP vaccine) is an effective postsurgical adjuvant treatment for melanoma patients with clinically evident nodal...
10.
Mastrangelo M, MAGUIRE Jr H, Sato T, Nathan F, Berd D
Semin Oncol
. 1996 Dec;
23(6):773-81.
PMID: 8970602
The bonafide albeit infrequent examples of tumor regression observed with whole tumor cell vaccines give evidence for the hypothesis that active specific immunization can induce a therapeutically effective immune response...